bluebird bio shared long-term data at the ASH Annual Meeting on ZYNTEGLO® (betibeglogene autotemcel), a one-time gene therapy for beta-thalassemia patients requiring regular transfusions. Results from up to 10 years of follow-up show durable transfusion independence, improved hemoglobin levels, reduced iron burden, and sustained safety outcomes. Most participants achieved long-term benefits, including discontinuation of iron chelation therapy and enhanced quality of life. The therapy continues to demonstrate its potential to transform the management of severe genetic diseases.